drugset / Trial / NCT00372996

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996

Phase 2 Terminated 219 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer

Timeline

Start
2007-02
Primary completion
2012-09
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exemestane Small molecule 25 mg Oral
Subject Figitumumab Monoclonal antibody 20 mg/kg Intravenous
Background Fulvestrant Small molecule

Indications